




INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 5 : A61F 9/00	A1	(11) International Publication Number: WO 91/18568 (43) International Publication Date: 12 December 1991 (12.12.91)
(21) International Application Number: PCT/US91/03837 (22) International Filing Date: 31 May 1991 (31.05.91)		(74) Agents: SIMPSON, Andrew, H. et al.; Knobbe, Martens, Olson and Bear, 620 Newport Center Drive, 16th Floor, Newport Beach, CA 92660 (US).
(30) Priority data: 531,010 31 May 1990 (31.05.90) US		(81) Designated States: AT (European patent), AU, BE (European patent), BR, CA, CH (European patent), DE (European patent), DK (European patent), ES (European patent), FR (European patent), GB (European patent), GR (European patent), IT (European patent), JP, KR, LU (European patent), NL (European patent), SE (European patent).
(71) Applicant : WRIGHT MEDICAL, INC. [US/US]; 34-B Mauchly Street, Irvine, CA 92718 (US).		
(72) Inventors: BAERVELD, George ; 989 S. Madison Avenue, Pasadena, CA 91106 (US). BLAKE, Larry, W. ; 10 Lexington, Irvine, CA 92720 (US). WRIGHT, George, M. ; 24145 Puerta De Luz, Mission Viejo, CA 92691 (US).		Published <i>With international search report.</i>

(54) Title: GLAUCOMA IMPLANT

(57) Abstract

An implant (10) for use in the treatment of glaucoma is disclosed wherein the implant (10) comprises an elastomeric plate (40) having a non-valved elastomeric drainage tube (42) attached thereto. The plate (40) is elliptical in shape and curved so as to conform to the curvature of the eye (12). The plate (40) is inserted into the eye (12) in an incision (70) made in the Tenon's capsule (44) and sutured to the sclera (14). The drainage tube (42) is tunnelled through the Tenon's capsule (44) and cornea (16) and inserted into the anterior chamber (30), thus providing patent fluid communication between the anterior chamber (30) and the elastomeric plate (40). The flexible structure of the plate (40) allows the plate to be easily inserted, thus reducing the surgical procedure length. In addition, the pliable material minimizes the risk of damage and trauma to surrounding tissues in the insertion process.



FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	ES	Spain	MG	Madagascar
AU	Australia	FI	Finland	ML	Mali
BB	Barbados	FR	France	MN	Mongolia
BE	Belgium	GA	Gabon	MR	Mauritania
BF	Burkina Faso	GB	United Kingdom	MW	Malawi
BG	Bulgaria	GN	Guinea	NL	Netherlands
BJ	Benin	GR	Greece	NO	Norway
BR	Brazil	HU	Hungary	PL	Poland
CA	Canada	IT	Italy	RO	Romania
CF	Central African Republic	JP	Japan	SD	Sudan
CG	Congo	KP	Democratic People's Republic of Korea	SE	Sweden
CH	Switzerland	KR	Republic of Korea	SN	Senegal
CI	Côte d'Ivoire	LJ	Liechtenstein	SU	Soviet Union
CM	Cameroon	LK	Sri Lanka	TD	Chad
CS	Czechoslovakia	LU	Luxembourg	TG	Togo
DE	Germany	MC	Monaco	US	United States of America
DK	Denmark				

-1-

GLAUCOMA IMPLANT

Field of the Invention

The invention relates to ocular implants, and, in
5 particular, to an implant used in the treatment of glaucoma.

Background of the Invention

Aqueous is a clear, colorless fluid that fills the anterior and posterior chambers of the eye. The aqueous is formed by the ciliary body in the eye and is a carrier of
10 nutrients for the lens. In addition, the aqueous provides a continuous stream into which surrounding tissues can discharge the waste products of metabolism.

The aqueous produced in the ciliary processes circulates from the posterior chamber to the anterior chamber of the eye through the pupil and is absorbed through the trabecular meshwork, a plurality of criss-crossing collagen cords covered by endothelium. Once through the trabecular meshwork, the aqueous passes through Schlemm's canal and into venous circulation. The rate of aqueous
20 outflow through the trabecular meshwork in a normal eye is typically 2.1 $\mu\text{L}/\text{min}$. Intraocular pressure in the eye is maintained by the formation and drainage of the aqueous. All the tissues within the corneoscleral coat covering the eyeball are subject to this pressure, which is higher than
25 pressure exerted on tissues at other locations in the body.

Glaucoma is a progressive disease of the eye characterized by a gradual increase of intraocular pressure. This increase in pressure is most commonly caused by stenosis or blockage of the aqueous outflow
30 channel, resulting in excessive buildup of aqueous fluid in the eyeball. Other causes include increase in venous pressure outside the eye which is reflected back through the aqueous drainage channels and increased production of aqueous. In a "normal" eye, intraocular pressure ranges
35 from 4 to 12 mm mercury. In an eye with glaucoma, this

-2-

pressure can rise to as much as 50 mm mercury. This increase in intraocular pressure produces gradual and permanent loss of vision in the afflicted eye.

Existing corrective methods for the treatment of 5 glaucoma include drugs, surgery, and implants. Miotic drugs lower intraocular pressure by facilitating aqueous outflow. Beta blockers, epinephrine products, and carbonic anhydrase inhibitors which inhibit production of the aqueous, are also commonly used in pharmacological glaucoma 10 treatment. Steroids have been used in long-term glaucoma treatment as well. However, pharmacological treatment is prohibitively expensive to a large majority of glaucoma patients. In addition, many people afflicted with the disease live in remote or undeveloped areas where the drugs 15 are not readily accessible. The drugs used in the treatment, in particular the steroids, often have undesirable side effects and many of the long-term effects resulting from prolonged use are not yet known.

Surgical procedures have been developed in an effort 20 to treat victims of glaucoma. An iridectomy, removal of a portion of the iris, is often used in angle-closure glaucoma wherein there is an occlusion of the trabecular meshwork by iris contact. Removal of a piece of the iris then gives the aqueous free passage from the posterior to 25 the anterior chambers in the eye. A trabeculotomy, opening the inner wall of Schlemm's canal, is often performed in cases of open-angle glaucoma so as to increase the outflow of the aqueous, thereby decreasing intraocular pressure. While often successful, these surgical techniques possess 30 inherent risks associated with invasive surgery on an already afflicted eye. Furthermore, the tissue of the eye can grow back to the pre-operative condition, thereby necessitating the need for further treatment.

Ocular implants are often used in long-term glaucoma 35 treatment without the disadvantages of drugs and invasive surgery. One such implant is disclosed in U.S. Patent No. 4,457,757 entitled "Device for Draining Aqueous Humor" and

-3-

commercially available as the Molteno™ Seton Implant. The implant comprises a drainage tube connected to one or more ridged plate reservoirs. The reservoir plates are designed to conform to the curvature of the eye. A reservoir plate 5 is placed under Tenon's capsule and sutured to the sclera. The drainage tube is implanted into the anterior chamber through a scleral flap. A second plate can be implanted under the superior rectus muscle and sutured to the sclera. At this point, the body will form a tissue around these 10 plates. Increased pressure causes the tissues above the plates to lift and form a bleb into which aqueous fluid from the anterior chamber drains via the drainage tube. Once inside the bleb, the aqueous seeps into intercellular spaces and is removed by surrounding capillaries or lymphatics. 15 This type of implant is disadvantageous as the plates are formed of a rigid plastic which makes insertion beneath the eye tissue difficult and time-consuming. Furthermore, the rigid material poses a risk of irritation and/or damage to adjacent vasculature and tissue.

20 UK Patent Application 2,160,778 entitled "Aqueous humor drainage device" discloses a similar type of implant device comprising a drainage tube and a drainage body. The tube is fixed to and opens directly onto a surface of the body. The device is sutured to the sclera of the eye and 25 the tube positioned within the anterior chamber so as to provide outflow for the aqueous contained therein. The device further includes a pressure gradient limiting valve formed as a slit in the tube, however, this type of valve does not allow patent, i.e., open or two-way, flow through 30 the drainage tube, thereby preventing retrograde aqueous flow into the anterior chamber.

Summary of the Invention

The present invention provides an implant for the treatment of glaucoma which can be easily inserted into an 35 afflicted eye and which provides for patent flow between the implant and the anterior chamber of the eye. The implant comprises a single plate formed of a pliable,

-4-

elastomeric material having a non-valved tube attached to and opening onto the upper surface of the plate. The pliable plate is sutured to the sclera and covered by a thick flap of Tenon's capsule so as to be encapsulated 5 within a drainage bleb. The attached tube is tunneled out through Tenon's capsule and in through the limbus so as to provide a drain for aqueous fluid. The exposed portion of the tube is covered by a scleral graft. Because of the pliable construction and shape, the device can be implanted 10 much quicker than previously realized with other implants. This substantially shortens the time required to perform the surgical procedure.

In a unique aspect of the invention, the plate is constructed so as to be radio-opaque. This allows the 15 implant to be easily viewed by X-ray after surgery, advantageously allowing progress monitoring. A suture is placed around the drainage tube and knotted to close off the tube and prevent initial flow between the anterior chamber and elastomeric plate. Once bleb tissue formation 20 is complete the suture is removed in a second surgical procedure. Alternatively, a dissolving suture can be used to secure the drainage tube.

In an alternative embodiment, the device includes a dissolving plug contained within the drainage tube. The 25 plug prevents the drainage of aqueous fluid until formation of the bleb is completed. Once bleb formation has occurred, the plug dissolves, allowing for unrestricted flow between the anterior chamber and bleb. Additional alternative embodiments are disclosed wherein the drainage 30 tube comprises double lumen tubing having a primary lumen and a substantially smaller secondary lumen. The primary lumen is provided with a dissolving plug which prevents aqueous flow until bleb formation is complete. The secondary lumen is provided with a flow restrictor or valve 35 to allow initial flow between the anterior chamber and bleb. In a further alternative embodiment, the drainage tube comprises first and second parallel drainage tubes

-5-

fitted with a dissolving plug and flow restrictor.

Brief Description of the Drawings

Figure 1 is a sectional view taken vertically through the upper, frontal portion of the eye, and Figure 2 is a schematic, perspective view of the eye, both illustrating the present invention implanted in a human eye;

5 Figure 3 and Figure 4 are perspective views illustrating the implant of the present invention;

Figure 5 is an alternative embodiment of the drainage tube;

10 Figures 5a through 5d are cross-sectional views illustrating various configurations of the drainage tube of Figure 5;

15 Figure 6 shows an additional alternative embodiment of the present invention;

Figure 7 illustrates a further embodiment of the implant.

Detailed Description of the Invention

Figure 1 and Figure 2 illustrate an implant 10 constructed in accordance with the present invention positioned within the tissue of an eye 12. The relevant structure of the eye 12 will be described briefly below so as to provide background for the anatomical terms incorporated herein, however, it should be realized that 20 several anatomical details have been omitted for clarity of understanding. The tough outer membrane known as the sclera 14 covers all of the eye 12 except that portion covered by the cornea 16, the thin, transparent membrane which covers the iris 18 and the pupil 20. The cornea 16 merges into the sclera 14 at a juncture referred to as the limbus 22. The ciliary body 26 begins at the limbus 22 and extends along the interior of the sclera 14 and becomes the choroid 28. The choroid 28 is a vascular membrane which 25 extends along the retina back toward the optic nerve.

30 It is well-known that aqueous is produced by the ciliary body 26 and reaches the anterior chamber 30 formed between the iris 18 and the cornea 16 through the pupil 20.

-6-

In a normal eye, the aqueous is removed through the trabecular meshwork 32. There the aqueous passes through Schlemm's canal 36 and through veins which merge with blood-carrying veins and into venous circulation.

5 Intraocular pressure is maintained in the eye 12 by the intricate balance of secretion and absorption or outflow of the aqueous in the manner described above. Glaucoma results from excessive buildup of aqueous fluid in the anterior chamber 30 which produces an increase in

10 intraocular pressure.

The present invention is designed for treatment of glaucoma by facilitating the outflow of the aqueous in the anterior chamber 30 of the eye 12. The implant 10 comprises a pliable carrier plate 40 connected to a

15 drainage tube 42. As illustrated in Figure 1, the carrier plate 40 is implanted in the eye 12 beneath a layer of Tenon's capsule 44 and sutured to the sclera 14. The discharge tube 42 comprises a first end 46 a second end 48 wherein the first end 46 is attached to the plate 40. The

20 second end 48 of the tube 42 extends through the layer of Tenon's capsule 44 and through the cornea 16 into the anterior chamber 30 of the eye 12. A scleral graft 50 covers the exposed portion of the tube 42 located between the Tenon's capsule 44 and the cornea 16. A large drainage

25 bleb 52 surrounds the carrier plate 40 and lifts the layer of Tenon's capsule 44 above the sclera 14.

The implant 10 is shown in more detail in Figure 2 and Figure 3. The carrier plate 40 is generally spherical in shape, and has a perimeter which is elliptical. The

30 surface area of the plate 40 is preferably in the range of 100 to 600 mm² depending on glaucoma condition and the radius of curvature of the plate is preferably 12 to 14 mm. The carrier plate 40 includes a raised ridge 56 formed adjacent one of the larger-radius perimeter edges of the

35 ellipse, on the convex spherical surface. The rounded edge of the plate 40 extending on either side of the raised ridge 56, not including that portion of the plate 40

-7-

adjacent the ridge 56, is entirely radiused, tapered, and blended so as to facilitate insertion as described below. The inner surface of the carrier plate 40 is concave so as to conform to the curvature of the eye 12 and the curvature of the ridge 56 matches the curvature of the sclera 14. An extension 58 of the carrier plate 40 is formed adjacent the ridge 56 and includes two small suture holes 60, 62. The thickness of the plate 40 is preferably in the range of 0.5 to 2.0 mm.

10 The drainage tube 42 is connected to the carrier plate 40 with adhesive, such as Clear Silicone Rubber Adhesive RTV-118 manufactured by General Electric Silicone Products of Waterford, New York, via a small hole 64 formed in the ridge 56 and is bonded to the plate 40 using well-known bonding techniques. The first end of the tube 46 thus drains into the recess formed at the junction of the ridge 56 and the smooth outer surface of the carrier plate 40. The plate 40 is preferably formed of silicone elastomer, such as SILASTIC™, Medical Grade Q7-4765, 65 Shore A, manufactured by Dow Corning Corporation of Midland, Michigan, although other silicone elastomers in the range of 40-85 Shore A and having good elastic memory are also suitable. The silicone elastomer is filled with a radiopaque material, such as Barium Sulfate, so that the 15 implant is visible in X-ray procedures, thereby allowing patient progress monitoring. The drainage tube 42 is preferably a 1.0 to 3.0 French flow tube, approximately 10 mm in length, formed of SILASTIC™, Medical Grade RX-50, also available from Dow Corning Corporation.

20 The present invention can be implanted using known ophthalmological surgical techniques and, with reference to Figure 1 and Figure 4, the surgical implant procedure will be briefly described. An initial incision 70 is made in the Tenon's capsule 44 proximal the limbus 22. The carrier 25 plate 40 is inserted through this incision 70 and positioned beneath the Tenon's capsule 44 and a portion of the rectus muscle 72, thus covering the sclera 14. The 30

-8-

carrier plate 40 can be sutured to the sclera 14, or alternatively, to the rectus muscle 72 if a larger implant 10 is used, with the suture holes 60, 62. The drainage tube 42 is tunneled out through the Tenon's capsule 44 and in through the limbus 22 such that the second end 48 of the tube 42 extends into the anterior chamber 30 of the eye 12. The exposed portion of the drainage tube 42 is then covered with the scleral graft 50. The drainage tube 42 is sutured closed with a suture(s) 74 to prevent any drainage of aqueous prior to formation of the bleb tissue 52 over the carrier plate 40.

The formation of the bleb 52 occurs in response to the introduction of the carrier plate 40 into the tissue of the eye 12. The bleb 52 comprises a thin layer of connective tissue which encapsulates the carrier plate 40, thus lifting the Tenon's capsule 44 above the sclera 14 as shown. Typically, bleb formation occurs in the range of 2 to 8 weeks postoperatively, at which time additional surgery can be performed to remove the suture 74 and allow flow of aqueous from the anterior chamber 30 to the bleb 52 via the drainage tube 42. Alternatively, a dissolving suture can be used to seal the drainage tube 42. After removal or dissolution of the suture 74 blocking the drainage tube 42, the aqueous flow between the tube 42 and bleb 52 is advantageously a patent flow, allowing for both flow from the anterior chamber 30 to the bleb 52 and vice versa. This ensures that retrograde flow from the bleb 52 to the anterior chamber 30, occurring in response to pressure on the eye 12 from the outside, for example, when the lid is forced closed or when the eyeball is pressed on with a finger, does not adversely or harmfully affect intraocular pressure within the eye 12. The fluid contained in the bleb 52 seeps through the bleb into intracellular spaces within eye 12 and is then removed through surrounding capillaries or lymphatics.

The flexible, elastomeric material used to form the present invention and its elliptical shape allow the

-9-

implant 10 to be inserted much more easily than previously realized with other glaucoma treatment implants. During the insertion process, the carrier plate 40 can be "folded" in half about the axis of the tube 42 and then inserted 5 through the incision 70. Once placed through the incision 70, the carrier plate 40 will return to its original shape and can be positioned so as to cover the sclera 14, as described above. Further, the material from which the plate 40 is formed is soft and pliable, which results in 10 much less trauma and irritation to the surrounding tissues and vasculature than experienced with a rigid plate device. In addition, since the plate 40 is folded, a smaller incision can be made in the Tenon's capsule 44. Thus, the 15 pliable carrier plate 40 significantly decreases the surgical procedure length while also minimizing tissue and vasculature damage which can occur in the insertion process.

In an alternative embodiment illustrated in Figure 5, the drainage tube 42 is formed as double lumen tubing 20 having a primary lumen 80 and a secondary lumen 82 substantially smaller than the primary lumen 80. A dissolving plug 84 is placed within the primary lumen 80 to ensure that the majority of aqueous flow does not begin until formation of the bleb 52 is complete. The secondary 25 lumen 82 is provided with a flow restrictor, small valve, or filter 86 which allows for a small amount of initial aqueous flow during bleb formation. The dissolving plug 84 is preferably formed of Poly Vinyl Alcohol (PVA), Poly Vinyl Pyrrolidone (PVP), enzymatically activated collagen, 30 or other biomedically suitable materials which slowly dissolve, thus gradually permitting the flow of aqueous and relieving intraocular pressure. As shown in Figures 5a through 5d, a variety of primary and secondary lumen 80, 82 configurations are possible. Although four configurations 35 are illustrated, one skilled in the art will recognize that various other embodiments could be constructed.

Another alternative embodiment of the present

-10-

invention is illustrated in Figure 6. Figure 6 illustrates an implant 88 having a carrier plate 40, a raised ridge 56, a plate extension 58, and suture holes 60, 62, essentially identical to that disclosed and shown in Figures 2 and 3
5 and numbered correspondingly. The implant 88 is attached to the eye 12 in the same manner as shown in Figures 1 and 4 so as to provide aqueous flow between the anterior chamber 30 and bleb 52. The implant 88 includes first and second parallel drainage tubes 90, 92 positioned adjacent the suture holes 60, 62 and bonded to the raised ridge 56.
10 The first discharge tube 60 is fitted with a dissolving plug 94 which slowly dissolves to provide gradual flow from the anterior chamber 30 to the bleb 52. As described above, the plug 94 is formed of a polymeric material such as PVP, PVA, or collagen. Alternatively, a ligature could
15 be used to secure the first tube 90 and control flow between the anterior chamber 30 and bleb 52. A micron filter or flow restrictor 96 is contained within the second discharge tube 62 to provide a relatively small amount of
20 initial flow between the anterior chamber 30 and bleb 52.

A further alternative embodiment of the invention is illustrated in Figure 7 wherein first and second discharge tubes 100, 102, are oriented in a "Y" configuration and merge into a single discharge tube 104 whose end 106 is placed inside the anterior chamber 30. As in the embodiment described above and illustrated in Figure 6, the first discharge tube 100 includes a dissolving plug 94 and the second discharge tube includes a flow restrictor or valve 96 placed therein. In this manner, aqueous flow is
25 controlled until formation of the bleb 52 is complete.
30

Although the invention has been described with reference to specific embodiments, the description is intended to be illustrative of the invention and is not intended to be limiting. Various modifications and
35 applications may occur to those skilled in the art without

departing from the true spirit and scope of the invention

-11-

as defined in the appended claims.

-12-

WHAT IS CLAIMED IS:

1. An implant (10) for draining aqueous fluid from the eye (12) characterized by:
 - a plate (40) for placement in tissue adjacent said eye (12);
 - a tube (42) attached to drain fluid from the vicinity of said plate (40) into the anterior chamber (30) of said eye (12); and
 - a dissolving flow restrictive plug (84) fitted within said tube (42).
 2. The implant (10) defined in Claim 1, wherein said plate (40) has a spherical surface contour conforming to the curvature of said eye (12).
 3. The implant (10) defined in Claim 1, wherein said plate (40) comprises first and second surfaces joined at a raised ridge (56).
 4. The implant (10) defined in Claim 3, wherein one of said first and second surfaces includes at least one aperture (60, 62) to suture said plate (40) to the sclera (14) of said eye (12).
 5. The implant (10) defined in Claim 1, wherein said plate (40) has a surface area which forms an ellipse.
 6. The implant (10) defined in Claim 5, wherein said plate (40) has a perimeter which is blended smooth.
 7. The implant (10) defined in Claim 1, wherein said plate (40) comprises a first surface having a raised ridge formed (56) along one edge thereof, said first surface having a tapered perimeter except at said one edge, said raised ridge having an aperture (64) formed therein.
 8. The implant (10) defined in Claim 7, wherein said tube (42) is bonded to said aperture (64) formed in said ridge (56).
 9. The implant (10) defined in Claim 1, wherein said plate (40) and said tube (42) are formed of thin silicone elastomer.
 10. The implant (10) defined in Claim 9, wherein said silicone elastomer of said plate (40) has a hardness in the

-13-

range of 40 to 85 Shore A.

11. The implant (10) defined in Claim 1, wherein said plate (40) is radio-opaque.

12. The implant (10) defined in Claim 1, wherein the 5 surface area of one side said plate (40) is in the range of 100 to 600 mm².

13. The implant (10) defined in Claim 1, wherein said tube (42) comprises a primary lumen (80) and a secondary lumen (82), said secondary lumen (82) having a diameter 10 smaller than the diameter of said primary lumen (80), said secondary lumen (82) providing initial flow between said eye (12) and said plate (40).

14. The implant defined in Claim 1, wherein said tube (42) comprises first and second drainage tubes (90, 92), 15 said first tube (90) having said dissolving plug (94) positioned therein and said second tube (92) having a flow restrictor (96) positioned therein, wherein said dissolving plug (94) and said flow restrictor (96) control aqueous flow between said plate (40) and said eye (12).

15. The implant (10) defined in Claim 1, wherein said dissolving plug (84) is formed of a biocompatible material.

16. The implant (10) defined in Claim 15, wherein said biocompatible material comprises collagen.

17. The implant (10) defined in Claim 15, wherein said 25 biocompatible material comprises PVA.

18. The implant (10) defined in Claim 1, wherein said tube (42) comprises first and second drainage tubes (90, 92), said first drainage tube (90) secured to said eye (12) with a ligature, said second drainage tube (92) having a 30 flow restrictor (96) positioned therein, wherein said ligature and said flow restrictor (96) control aqueous flow between said plate (40) and said eye (12).

19. The implant (10) defined in Claim 1, wherein said plate (40) is positioned within a bleb (52) formed between 35 the sclera (14) and the Tenon's capsule (44) of said eye (12).

-14-


20. The implant (10) defined in Claim 1, wherein said plate (40) has a center and first and second edges, said first edge being thinner than said center, said plate having a ridge (56) formed at said second edge wherein said ridge 5 (56) has an aperture (64) formed therein.

21. The implant (10) defined in Claim 1, wherein said plate (40) has sufficient resilience so that if said plate (40) is folded flat against itself and released said plate (40) will return to its original as-molded condition.

10 22. The implant (10) defined in Claim 1, wherein said plate (40) further includes first and second apertures (60, 62) which provide first and second suture locations to attach said plate (40) to said eye (12).


1/5

FIG. 1



2/5

FIG. 2



SUBSTITUTE SHEET

3/5




FIG. 3











FIG. 4

SUBSTITUTE SHEET

4/5

FIG. 5**FIG. 5a****FIG. 5b****FIG. 5c****FIG. 5d**

5/5

FIG. 6**FIG. 7**

INTERNATIONAL SEARCH REPORT

PCT/US 91/03837

International Application No

I. CLASSIFICATION OF SUBJECT MATTER (if several classification symbols apply, indicate all)⁶

According to International Patent Classification (IPC) or to both National Classification and IPC

Int.Cl. 5 A61F9/00

II. FIELDS SEARCHED

Minimum Documentation Searched⁷

Classification System	Classification Symbols	
Int.Cl. 5	A61F ;	A61M

Documentation Searched other than Minimum Documentation
to the Extent that such Documents are Included in the Fields Searched⁸III. DOCUMENTS CONSIDERED TO BE RELEVANT⁹

Category ¹⁰	Citation of Document, ¹¹ with indication, where appropriate, of the relevant passages ¹²	Relevant to Claim No. ¹³
Y	US,A,4 457 757 (MOLTENO) July 3, 1984 cited in the application	1-4,6,9, 12,15, 16,19 7,8,22
A	see the whole document	---
Y	US,A,4 722 724 (SCHOCKET) February 2, 1988	1-4,6,9, 12,15, 16,19
A	see claims 1,2,4	---
A	EP,A,168 201 (HOWARD) January 15, 1986 cited in the application	14,18
A	see claim 1	---
A	GB,A,2 187 963 (MOLTENO) September 23, 1987	---
A	EP,A,102 747 (WHITE) March 14, 1984	---

¹⁰ Special categories of cited documents:

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

¹¹ "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention¹² "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step¹³ "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.¹⁴ "&" document member of the same patent family

IV. CERTIFICATION

Date of the Actual Completion of the International Search

Date of Mailing of this International Search Report


12 SEPTEMBER 1991

26.09.91

International Searching Authority

Signature of Authorized Officer

EUROPEAN PATENT OFFICE

VILLENEUVE J.M. 

ANNEX TO THE INTERNATIONAL SEARCH REPORT
ON INTERNATIONAL PATENT APPLICATION NO.

US 9103837
SA 49027

This annex lists the patent family members relating to the patent documents cited in the above-mentioned international search report.
The members are as contained in the European Patent Office EDP file on
The European Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

12/09/91

Patent document cited in search report	Publication date	Patent family member(s)			Publication date
<hr/>					
US-A-4457757	03-07-84	None			
US-A-4722724	02-02-88	US-A-	4826478	02-05-89	
EP-A-168201	15-01-86	AU-A- CA-A- DE-A- GB-A, B JP-A- US-A-	4412585 1238833 3563415 2160778 61082748 4604087	02-01-86 05-07-88 28-07-88 02-01-86 26-04-86 05-08-86	
GB-A-2187963	23-09-87	US-A-	4750901	14-06-88	
EP-A-102747	14-03-84	US-A- CA-A- JP-A-	4554918 1235854 59040854	26-11-85 03-05-88 06-03-84	

This Page Blank (uspto)